Vertex Pharmaceuticals

Vertex Pharmaceuticals

Heme, Research Fellow

Boston, MA · Senior

Sponsorship not specified$197k-$296kDetected 6 hours ago
GCPA/B TestingRecruitingPharmacologyFDA RegulatoryCRISPRResearchAnimal StudiesLeadershipPublic Speaking

Stay score

odds of building a lasting career here

59Sponsors, lottery-bound
Cap-exempt (no lottery)0
Sponsors this role82
Entry-level history0
PERM / green-card track0
Lottery odds (Level IV)94
Fits your clock70

Sponsors, but it's cap-subject — you still face the weighted lottery (~61% per draw at Level IV). Good if you win; have a cap-exempt backup on your list.

Lottery odds assume a STEM candidate.

Personalize to your clock →

H-1B wage level

the lottery is wage-weighted — each level is one more entry

Level IV · 4×
Level I$85,5501 entry
Level II$109,5332 entries
Level III$133,4943 entries
Level IV$157,4774 entries

This range already reaches Level IV — the maximum four lottery entries.

DOL prevailing wage, 2026-27 wage year · Medical Scientists, Except Epidemiologists (19-1042) · Boston-Cambridge-Newton, MA-NH. Wage level is derived by USCIS from the offered wage, occupation and worksite; the occupation shown is inferred from the job title.

Employer immigration record

from this employer's Department of Labor filings

Green-card follow-through: 83%

Of 12 labor certifications old enough to have been used, 2 expired without the employer filing the next step. Median time from filing to decision: 515 days.100% of their filings were for a worker who already held the job.Only certifications past the 180-day window are counted — recent ones cannot have expired yet.

Files H-1B transfers

29 transfer filings in the last year, covering 29 workers. Median labor-condition decision: 7 days. An employer that already files transfers is one that can take over an existing H-1B.

Sourced from Department of Labor LCA, PERM and prevailing-wage disclosure data. Employer matching is by name, so figures may be split across an employer's legal entities. Absence of a filing means none appears in our copy of the data, not that none exists.

Community outcomes

No reports yet — be the first to help the next applicant.

About the role

  • The primary focus is to advance in vivo gene editing programs from preclinical proof-of-concept through IND-enabling studies and into Phase 1/2 trials.
  • This leader will bridge clinical expertise with translational science to shape disease strategy, direct preclinical and translational research, and define the path to first-in-human studies.
  • Serve as a physician-scientist leader for IND-enabling strategy in partnership with development, regulatory, and clinical teams

Responsibilities

  • Lead scientific strategy for in vivo gene editing platforms, including editing technologies, delivery approaches, tissue targeting, and integrated pharmacology/toxicology
  • Provide disease and mechanistic insight to support target selection, hypothesis testing, and candidate optimization
  • Design and guide in vitro, ex vivo, and in vivo studies tied to clinically meaningful biology
  • Lead cross-functional project teams to set goals, priorities, timelines, budgets, and decision points
  • Integrate scientific, translational, and clinical considerations to drive programs toward development candidate nomination
  • Help build a strong, collaborative, high-performing research culture

Requirements

  • MD and/or PhD in a relevant discipline with 11+ years in academic medicine, translational research, biotech, pharma R&D, or related settings
  • Strong expertise in drug development, translational science, and disease biology
  • Demonstrated scientific leadership, publication record, and ability to influence project direction
  • Experience in cell and gene therapy, genome editing, or in vivo pharmacology
  • Track record in hemoglobinopathies, translational therapeutics, gene therapy, gene editing, stem cell biology, or related fields
  • Direct experience in hemoglobinopathies (e.g., sickle cell disease, thalassemia, erythropoiesis, globin regulation)
  • Experience with IND-enabling programs and translation to first-in-human strategy
  • Familiarity with delivery systems, editing efficiency, durability, tissue specificity, and off-target risk
  • Knowledge of HSC biology, stem cell phenotyping, engraftment, and ex vivo manipulation
  • Experience with conditioning strategies for cell/gene therapy or transplantation

Nice to have

  • Preferred Experience

Compensation

  • $197,400 - $296,200
  • The range provided is based on what we believe is a reasonable estimate for the base salary pay range for this job at the time of posting.
  • This role is eligible for an annual bonus and annual equity awards.
  • Some roles may also be eligible for overtime pay, in accordance with federal and state requirements.
  • Actual base salary pay will be based on a number of factors, including skills, competencies, experience, and other job-related factors permitted by law.

Company info

  • We are seeking an innovative physician-scientist to lead drug discovery and translational research within the Hemoglobinopathies Research Group.

Equal opportunity

  • Any applicant requiring an accommodation in connection with the hiring process and/or to perform the essential functions of the position for which the applicant has applied should make a request to the recruiter or hiring manager, or contact Talent Acquisition at ApplicationAssistance@vrtx.com

This listing is sourced directly from Vertex Pharmaceuticals's careers page and normalized into a canonical job model.